Categories: Artificial IntelligenceHealthTechMarketMedtechPersonalPlatformTechnology
Nerai pioneers novel highly personalized CRISPR proteins to deliver lifelong cures for diseases beyond the reach of current genome editing. By fusing AI with programmable biology, its editors redefine what is achievable in the safety, efficiency, and targetability of genetic medicine. With lead programs unlocking $3.3B market potential in rare liver disease and strong biopharma traction for its platform technology, Nerai is poised to become a key European-based player in vivo genome editing.
Investors 1
Mentions in press and media 4
| Date | Title | Description |
| 26.03.2025 | Venture Leaders Biotech 2025 cohort revealed |
After reviewing over 70 applications, the jury of investors and biotech experts selected the ten startups to participate in the Boston roadshow, one of the world’s leading life science hubs. The Venture Leaders program will allow the selec... |
| 11.11.2024 | Nerai Bio obtains funding to release the full potential of genome editing |
One in ten people worldwide is affected by genetic diseases, and over 90% of them lack approved therapies. Genome editing has revolutionized the way we think and treat these disorders. However, most current technologies like CRISPR (Cluste... |
| 05.07.2024 | InnoBooster injects CHF 750,000 in five projects |
The InnoBooster program an initiative of the Gebert Rüf Stiftung supports university-based, high-potential business cases from the Venture Kick program with the aim of substantially accelerating their market entry. The program provides up ... |
| - | Nerai Bio | “nerai bio” |
Reviews 0
